| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
1,770,000,000 |
| Market
Cap: |
282.53(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$132.51 - $182.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 560 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
459,004 |
461,916 |
540,416 |
1,579,317 |
| Total Sell Value |
$81,195,771 |
$81,646,316 |
$93,320,391 |
$252,708,726 |
| Total People Sold |
9 |
9 |
9 |
14 |
| Total Sell Transactions |
10 |
11 |
13 |
37 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siatis Perry C |
EVP, GC AND SECRETARY |
• – – |
2024-02-23 |
4 |
OE |
$105.92 |
$1,889,115 |
D/D |
13,753 |
41,926 |
|
- |
|
| Saleki-Gerhardt Azita |
EVP, CHIEF OPERATIONS OFFICER |
• – – |
2024-02-21 |
4 |
S |
$173.71 |
$9,184,048 |
D/D |
(52,870) |
243,944 |
|
4% |
|
| Saleki-Gerhardt Azita |
EVP, CHIEF OPERATIONS OFFICER |
• – – |
2024-02-21 |
4 |
OE |
$58.88 |
$3,112,986 |
D/D |
52,870 |
296,814 |
|
- |
|
| Buckbee Kevin K |
SVP, CONTROLLER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,048 |
19,211 |
|
- |
|
| Saleki-Gerhardt Azita |
EVP, CHIEF OPERATIONS OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
54,095 |
243,944 |
|
- |
|
| Michael Robert A. |
PRES & CHIEF OPERATING OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
84,957 |
183,602 |
|
- |
|
| Richmond Timothy J. |
EVP, CHIEF HR OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
53,827 |
67,664 |
|
- |
|
| Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
• • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
248,865 |
772,159 |
|
- |
|
| Siatis Perry C |
EVP, GC AND SECRETARY |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,796 |
28,173 |
|
- |
|
| Stewart Jeffrey Ryan |
EVP, CHIEF COMMERCIAL OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
58,960 |
119,901 |
|
- |
|
| Donoghoe Nicholas |
EVP, CHIEF BUS/STRAT OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,853 |
93,756 |
|
- |
|
| Thakkar Roopal |
SVP, CMO, GLOBAL THERAPEUTICS |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,796 |
28,173 |
|
- |
|
| Hudson Thomas J |
SVP, CSO, GLOBAL RESEARCH |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
46,572 |
127,901 |
|
- |
|
| Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,256 |
27,065 |
|
- |
|
| Siatis Perry C |
EVP, GC AND SECRETARY |
• – – |
2024-02-02 |
4 |
D |
$170.00 |
$496,230 |
D/D |
(2,919) |
10,377 |
|
- |
|
| Siatis Perry C |
EVP, GC AND SECRETARY |
• – – |
2024-02-02 |
4 |
A |
$144.54 |
$421,912 |
D/D |
2,919 |
13,296 |
|
- |
|
| Donoghoe Nicholas |
EVP, CHIEF BUS/STRAT OFFICER |
• – – |
2023-12-26 |
4 |
S |
$154.72 |
$450,545 |
D/D |
(2,912) |
55,903 |
|
-8% |
|
| Thakkar Roopal |
SVP, Global Therapeutics & CMO |
• – – |
2023-12-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,225 |
|
8% |
|
| Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
• • – |
2023-09-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
42,000 |
523,294 |
|
- |
|
| Alpern Robert J |
|
– • – |
2023-09-07 |
4 |
A |
$0.00 |
$0 |
D/D |
129 |
33,121 |
|
- |
|
| Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
• • – |
2023-08-01 |
4 |
S |
$148.58 |
$8,914,800 |
D/D |
(60,000) |
565,294 |
|
0% |
|
| Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
• • – |
2023-07-31 |
4 |
S |
$149.15 |
$2,759,275 |
D/D |
(18,500) |
625,294 |
|
2% |
|
| Donoghoe Nicholas |
EVP, Chief Bus/Strat Officer |
• – – |
2023-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
58,815 |
|
6% |
|
| Strom Carrie C |
SVP & PRES GLOBAL ALLERG AESTH |
• – – |
2023-05-11 |
4 |
D |
$146.42 |
$421,104 |
D/D |
(2,876) |
28,024 |
|
- |
|
| Tilton Glenn F |
|
– • – |
2023-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,450 |
49,039 |
|
- |
|
641 Records found
|
|
Page 2 of 26 |
|
|
7.67 (4.58%) 
